RHHBY obtains FDA approval for Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

A new breast cancer drug has received quick federal approval after a clinical trial showed it could more than double the time before a common type of breast cancer recurrence worsens.

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Significant research news last week saw US biotech Scholar Rock release positive new data for its spinal atrophy (SMA) ...

Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...

Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its ...

Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...

Patients with endocrine-resistant, HER2-negative, locally advanced or metastatic breast cancer can use the treatment after ...

In the INAVO120 trial, Itovebi added to Pfizer's Ibrance and fulvestrant doubled progression-free survival versus Ibrance and fulvestrant alone.

Roche (RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of breast ...